Melbourn promotes Derek Solomon

Moves from laboratory manager to operations director

Melbourn Scientific, a UK provider of analytical and formulation contract research services for the pharma and biotech industries, is broadening its management team with the promotion of laboratory manager Derek Solomon to the new role of operations director.

Solomon joined Melbourn Scientific in 2005 and has overseen the expansion of the services portfolio, which included the recent addition of clinical manufacture to its formulation development services.

You may also like

Research & Development

Intertek acquires Melbourn Scientific

Combines advanced capabilities for measuring device/drug interaction with OINDP drug characterisation expertise
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A finite resource: helium

Although helium may be the second most abundant element in the universe, here on earth this noble gas is rare and precious. In the pharmaceutical industry helium is used for cryogenic cooling of magnets used for MRI and in gas chromatography
Research & Development

Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing

Helping biopharma labs reach new heights in analytical performance
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Subscribe now